Strides Pharma Science Ltd (STAR) Q4FY26 Management Mirror - Mar-2026 Qtr
U.S. Revenue Target
The Mar'26 Qtr reaffirmed the long-term U.S. revenue aspiration of $375 million to $400 million by Mar'28, consistent with Sep'25 Qtr and Dec'25 Qtr guidance, with expectations for sequential growth and the full potential of new product launches materializing by H2 FY27. [Status: Reaffirmed]
5 more themes on the ELITE plan.